MedTrace Logo

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

NCT01797276 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-08-08

No results posted yet for this study

Summary

Expanded access to DCA as continued treatment for congenital lactic acidosis.

Conditions

  • Mitochondrial Enzyme Deficiencies

Interventions

DRUG

Dichloroacetate

Subjects are given DCA 25mg/kg in a divided dose twice a day.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Peter W. Stacpoole, PhD, MD · University of Florida

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797276 on ClinicalTrials.gov